#South Korea #financial results #Samsung Biologics #Incheon #CDMO

Samsung Biologics Achieves Impressive Financial Results in Q3 2026

Samsung Biologics, a leading contract development and manufacturing organization (CDMO), has reported remarkable financial performance for the third quarter of 2026. The figures show a revenue of KRW 1,490 billion and an operating profit of KRW 640 billion, reflecting the success of its strategic investments and commitment to meeting evolving pharmaceutical demands.

Strong Performance Driven by Expanded Capacity

During the third quarter, Samsung Biologics operated its Plants 1 through 4 at full capacity while also witnessing significant contributions from Plant 5 as it ramped up production. Moreover, the company’s Rockville manufacturing facility in the United States marked its first contribution to revenue, illustrating the success of Samsung Biologics' expansion efforts.

President and CEO John Rim emphasized the importance of adaptability to changing market needs, stating, "As global pharmaceutical pipelines become more diverse and supply requirements increasingly complex, the ability to execute consistently across manufacturing programs is ever more important." With this in mind, Samsung Biologics is strategically focused on enhancing its manufacturing capabilities to better serve clients in a rapidly changing landscape.

Updated Financial Guidance for 2026

Recognizing the positive trajectory and operational performance, Samsung Biologics has raised its revenue growth guidance for 2026 to 20%, up from a previous estimate of 15-20%. This adjustment highlights the company's confidence in its ability to deliver value to clients and achieve sustained growth.

In tandem with this growth outlook, Samsung Biologics is implementing operational excellence through its ExellenS™ framework, which standardizes facility designs, processes, and integrates advanced digital technologies. This framework is designed to enhance manufacturing readiness and support consistency across its production network.

Future Initiatives and Expansions

In October, Samsung Biologics took significant steps towards expanding its global footprint by opening a sales office in the Netherlands. This move further strengthens its engagement with European pharmaceutical and biotechnology companies, situating the company for enhanced collaboration and growth opportunities in a key global market.

Additionally, Samsung Biologics recently reported a successful interim outcome for the public tender offer for the PolyPeptide Group, achieving an impressive 87.92% acceptance rate. This acquisition is set to expand Samsung Biologics' service offerings into peptide-based therapeutics, further diversifying its portfolio and aligning with market demand.

To support these strategic initiatives, the company has announced a KRW 3 trillion rights offering aimed at funding the PolyPeptide acquisition and planned future manufacturing capacity expansions. Existing shareholders will have the opportunity to subscribe in November, with additional offerings planned for the general public if shares remain unsold.

Commitment to Sustainability

On the sustainability front, Samsung Biologics has garnered an 'A' rating in the latest MSCI ESG Ratings assessment, showcasing its ongoing commitment to sustainable business practices. The company has established a greenhouse gas emissions calculation system, enhancing its data management capabilities and ensuring readiness for forthcoming mandatory ESG disclosures.

As Samsung Biologics looks ahead, it remains dedicated to optimizing operational performance while effectively implementing strategic investments. The company is committed to enriching its capabilities to support clients globally and across a broader array of modalities.

For more detailed insights into the financial performance and operational updates, Samsung Biologics recommends referring to their latest Earnings Release.

About Samsung Biologics

Founded in Incheon, South Korea, Samsung Biologics is a premier provider of contract development and manufacturing services with a global network that spans multiple countries including the U.S., Europe, and Japan. With a focus on innovation and quality, the company helps in the development and commercial manufacturing of biopharmaceuticals. To stay updated on the latest developments and innovations, please visit Samsung Biologics.